Faculty, Staff and Student Publications
Open-access journal articles from UTHealth GSBS faculty, staff and students.
Submissions from 2023
The Phase 1/2 Trial of Indomethacin in Chronic Pancreatitis (the Pair Trial): Protocol for a Parallel Multi-Center Randomized Controlled Trial, Samuel Han, Darwin L Conwell, Liang Li, et al.
Multitrait Genome-Wide Analyses Identify New Susceptibility Loci and Candidate Drugs to Primary Sclerosing Cholangitis, Younghun Han, Jinyoung Byun, Catherine Zhu, et al.
Itch and Janus Kinase Inhibitors, Yujin Han, Yu Ri Woo, Sang Hyun Cho, et al.
Osteoprogenitor-GMP Crosstalk Underpins Solid Tumor-Induced Systemic Immunosuppression and Persists After Tumor Removal, Xiaoxin Hao, Yichao Shen, Nan Chen, et al.
An Ontology-Based Approach For Harmonization and Cross-Cohort Query of Alzheimer’S Disease Data Resources, Xubing Hao, Xiaojin Li, Guo-Qiang Zhang, et al.
Differential Effects of Bariatric Surgery and Caloric Restriction on Hepatic One-Carbon and Fatty Acid Metabolism, Arnon Haran, Michael Bergel, Doron Kleiman, et al.
Severe Arsenic Poisoning Due to Ayurvedic Supplements, Jeremy Hardin, Justin Seltzer, Raymond Suhandynata, et al.
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial, Kevin J Harrington, Robert L Ferris, Maura Gillison, et al.
The New NCI Precision Medicine Trials, Lyndsay N Harris, Charles D Blanke, Harry P Erba, et al.
Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary?, Isha Harshe, Heiko Enderling, and Renee Brady-Nicholls
Plastic, It's What's for Dinner: A Preliminary Comparison of Ingested Particles in Bottlenose Dolphins and Their Prey, Leslie B Hart, Miranda Dziobak, Randall S Wells, et al.
A Reduced Pancreatic Polypeptide Response is Associated With New-onset Pancreatogenic Diabetes Versus Type 2 Diabetes, Phil A Hart, Yogish C Kudva, Dhiraj Yadav, et al.
Changes in Outcomes and Factors Associated With Survival in Melanoma Patients With Brain Metastases, Merve Hasanov, Denái R Milton, Alicia Bea Davies, et al.
Type 2 Diabetes Modifies the Association of Cad Genomic Risk Variants With Subclinical Atherosclerosis, Natalie R Hasbani, Kenneth E Westerman, Soo Heon Kwak, et al.
Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis, Ken Hasegawa, Andrew H Wei, Guillermo Garcia-Manero, et al.
Mesothelin-Targeting T Cell Receptor Fusion Construct Cell Therapy in Refractory Solid Tumors: Phase 1/2 Trial Interim Results, Raffit Hassan, Marcus Butler, Roisin E O'Cearbhaill, et al.
The Application of Simultaneous Mainstem Bronchus Dilation With Pulmonary Artery Stenting in the Context of Hypoplastic Left Heart Syndrome, Sylwia Hasterok, Thomas G Scott, Devin G Roller, et al.
Nanobomb Optical Coherence Elastography in Multilayered Phantoms, Maryam Hatami, Dmitry Nevozhay, Manmohan Singh, et al.
New Insights About Immune Populations in Gastrointestinal GVHD, Eiko Hayase and Robert R Jenq
Cardiovascular Disease Risk Factors Among Middle-Aged and Older Adult Vietnamese American Members of a Northern California Health Plan, Donna B Haysbert, Joan C Lo, Nirmala D Ramalingam, et al.
Saturated Fatty Acids Dampen the Immunogenicity of Cancer by Suppressing STING, Blake R Heath, Wang Gong, Hülya F Taner, et al.
CurQ+, a Next-Generation Formulation of Curcumin, Ameliorates Growth Plate Chondrocyte Stress and Increases Limb Growth in a Mouse Model of Pseudoachondroplasia, Jacqueline T Hecht, Alka C Veerisetty, Mohammad G Hossain, et al.
Early Resveratrol Treatment Mitigates Joint Degeneration and Dampens Pain In A Mouse Model of Pseudoachondroplasia (Psach), Jacqueline T Hecht, Alka C Veerisetty, Debabrata Patra, et al.
Inhibition of Autophagy In Microglia and Macrophages Exacerbates Innate Immune Responses and Worsens Brain Injury Outcomes, Nivedita Hegdekar, Chinmoy Sarkar, Sabrina Bustos, et al.
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy, Kai He, David Berz, Shirish M Gadgeel, et al.